ISOFOL
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, one of the world's most common cancers, where the medical need for better treatments is great.
Read moreRevenue M
EBIT-% (adj.)
EPS (adj.)
Dividend %
Interim report Q3'26
Annual report '26
Don't miss out - create an account and get all the possible benefits